Elucid
Elucid is a Boston-based company specializing in AI-powered imaging analysis software for cardiovascular disease assessment, featuring FDA-cleared technology that enhances the prediction of cardiac events.
Company Overview
Elucid is a company specializing in AI-powered imaging analysis software designed to assess cardiovascular disease. The company aims to revolutionize the field of cardiovascular risk assessment through its advanced non-invasive diagnostic tools. Headquartered in Boston, MA, Elucid's technologies are built to offer unprecedented specificity in assessing plaque stability and vessel structure.
Funding and Financials
Elucid successfully raised $80 million in Series C funding, led by Elevage Medical Technologies. This funding is earmarked for the commercialization and expansion of Elucid's AI-powered non-invasive diagnostic tools for cardiovascular risk assessment.
Technologies and Innovations
Elucid has developed advanced imaging analysis software, including the FDA-cleared CTA analysis software that provides specific insights into plaque stability and vessel structure based on histology. Their PlaqueIQ™ technology uses CT angiography and patented computer algorithms to objectively quantify the extent and stability of arterial plaque. This technology achieves 87% accuracy in predicting major adverse cardiac events and offers 40% better stroke prediction compared to current stenosis-based guidelines.
Clinical Research and Publications
Elucid's technologies are supported by over 40 years of clinical research. The company has been involved in 12 clinical studies and has over 70 publications that validate the efficacy and reliability of their diagnostic tools.
Office Location
Elucid is headquartered at 2 Park Plaza, Suite 700, Boston, MA 02116. This strategic location supports their operations and expansion efforts in the field of cardiovascular disease diagnostics.